title

Novel Targets

Novel Targets

3
Followers
1
Plays
Novel Targets

Novel Targets

Novel Targets

3
Followers
1
Plays
OVERVIEWEPISODESYOU MAY ALSO LIKE

Details

About Us

Bringing to life the science around innovative new drugs, gene and cell therapies.Novel Targets is a science podcast that captured a landmark period in cancer research from 2015-18.

Latest Episodes

Episode 26: Coming Full Circle

The award of this year's Nobel prize in physiology or medicine to Dr Jim Allison and Dr Tasuku Honjo is a defining moment for cancer research that we want to recognize. You'll hear from Dr Allison on the very day he heard the announcement. We also take a closer look at what it takes to be a great scientist and explore the limitations on how many people the Nobel prize can recognize in a given year. If you want to increase your chance of winning, 1993 laureate Sir Richard Roberts FRS takes us through his "Ten Simple Rules to Win a Nobel Prize." We have come full circle in our journey over the last 3.5 years and now hear the results of a "practice changing" phase 3 cancer immunotherapy trial in triple negative breast cancer (TNBC) that we first talked about in the inaugural episode of the podcast, "The Checkpoints Show." There's also an update from the recent ESMO congress onresults from a phase 3 ovarian cancer trial that is potentially "life changing" for women with a BRCA mutation....

38 MIN2018 NOV 27
Comments
Episode 26: Coming Full Circle

Episode 25: In the shadow of T cells

In this episode we continue our journey looking at the innate immune system and focus on some important immune cells called natural killer (NK) cells and their potential in cancer immunotherapy. You'll hear from both academic and industry experts who are active in research in this field, including Dr Todd Fehniger (Washington University in St Louis), Dr Michael Caligiuri (City of Hope), Dr Jeff Miller (Minnesota), Prof Eric Vivier (Innate Pharma via Marseille Immunopole), Dr Nick Huntington (Walter & Eliza Hall Institute in Melbourne), Dr James Gulley (NCI), and Dr Deepak Sampath (Genentech). Some important topics we will cover: - What are NK cells? - What do the do? - How do they 'see'? - How can they be boosted? - What kind of approaches have been developed therapeutically? - What kind of clinical data have we seen so far? - What's the vision for the future of NK cell therapy development? You can find more detailed information about the topics discussed in the show notes on https:...

41 MIN2018 SEP 21
Comments
Episode 25: In the shadow of T cells

Episode 24: Immune System Choreography

In this episode we explore the innate immune system and find out what it is, what it does and why it matters in both health and disease. You'll hear various perspectives from both academic and industry experts who are active in research in this field, including Dr Glen Barber (Miami), Prof George Coukos (Lausanne), Dr Adi Diab (MD Anderson), Dr Tom Dubensky (Tempest Therapeutics via Aduro Biotech), Dr Tom Gajewski (Chicago), Dr Jonathan Lancaster (Myriad), Dr Ira Mellman (Genentech), Prof Eric Vivier (Innate Pharma via Marseille Immunopole/CIML), Dr Jonathan Zalevsky (Nektar Therapeutics). Some important topics we will cover: - What is the innate immune system? - What does it do? - How is it different from the adaptive immune system? - Is it really separate from the adaptive system? - STING (Stimulator of Interferon Genes) - Biomarkers - Toll-like Receptors (TLRs) You can find more detailed information about the topics discussed in the show notes on https://noveltargets.com. These i...

35 MIN2018 AUG 31
Comments
Episode 24: Immune System Choreography

Episode 23: Modulating the Signal

In this episode we take a look a look at how cytokines can be employed to modulate the tumour microenvironment in favourable ways. You'll hear various perspectives from numerous academic and industry experts who are active in research in this field, including Dr Mario Sznol (Yale), Dr James Gulley (NCI), Dr Adi Diab (MD Anderson), Dr Jonathan Zalevsky (Nektar Therapeutics), Dr Sanjeev Mariathasan (Genentech), Prof Tom Powles (Barts Cancer Institute), Dr Kunle Odunsi (Roswell Park), and Dr Renier Brentjens (Memorial Sloan Kettering). Some important topics that we will cover: - What are cytokines? - Why do they matter? - The good and bad effects they can induce on the tumour microenvironment (TME) - Interleukins - Transforming Growth Factor beta (TGFβ) - The increasingly important role for reverse translation research in helping to understand what's going on in the TME in order to improve rational future immuno-oncology (IO) combination approaches - Can we determine differences in re...

36 MIN2018 JUL 5
Comments
Episode 23: Modulating the Signal

Episode 22: Practice, Pitfalls, and Possibilities

Welcome back to Season 4! In this latest episode, we take a look at data from immunotherapy clinical trials from several different angles and investigate the challenges associated presented by different combination partners, control arms, patient populations, biomarkers, line of therapy, etc. When important phase 3 readouts hit the newswires, inevitable questions follow: - Is the data practice changing? - Which regimen should be used with which patient population? - What happens on the Weds after the conference in the clinic when a new patient presents; will oncologists do anything differently? While it's nice to have several positive trial results, how do physicians go about making sense of them? What are some of the hidden pitfalls of cross-trial comparisons that we should watch out for and consider? Professor Tom Powles (Barts Cancer Centre, London) is our narrator for this show and walks us through various challenges and opportunities that both investigators and oncologists face...

38 MIN2018 MAY 10
Comments
Episode 22: Practice, Pitfalls, and Possibilities

Episode 21: Playing With Fire

In this episode we're exploring some controversial issues in cancer research including real world versus clinical trial experience and immune related toxicities, as well as highlighting strength and weaknesses around some encouraging new data with several therapies in development for different hematologic malignancies. Not everything about cancer immunotherapies is positive -- there are challenges associated with this promising approach too. Despite what many people may believe, it's not just about merely tweaking one's immune system and the cancer goes away. Most of the interviews you'll hear were recorded at the 2017 annual meeting of the American Society of Hematology (ASH) in Atlanta. In this episode you'll hear leading experts, including Drs Paul Richardson and Philippe Armande (Dana-Farber), Dr John Leonard (Weill Cornell), Dr Ian Flinn (Sarah Cannon), Dr Nancy Simonian (Syros) and Drs Michael Wenger and Deepak Sampath (Genentech). Some of the topics covered include: * Real wo...

44 MIN2018 JAN 6
Comments
Episode 21: Playing With Fire

Episode 20: Cancer Vaccine Renaissance

In this latest episode we're exploring an up and coming area of cancer research, namely therapeutic cancer vaccines. If we want to jumpstart the immune system in cold/non-inflamed/desert tumours, then we need to find ways to attract more T cells into the tumour(s). Cancer vaccines can potentially do that but they have had a bit of a chequered history, with many failures and at least in the US, only one has been approved by the FDA to date. In this show you'll hear from leading cancer immunotherapy experts involved in cancer vaccine research, including Dr Cathy Wu (Dana Farber), Prof Ton Schumacher (Netherlands Cancer Institute), Prof Ugur Sahin (BioNTech and TRON), Prof Kees Melief (Leiden and ISA Pharma), Prof George Coukos (Lausanne), and Dr Ira Mellman (Genentech). Some important topics we cover include: - What's different about the next generation cancer vaccine approaches? - Neoantigen and neoepitope approaches - DNA and RNA vaccines - HPV vaccines - Dendritic cell vaccines - I...

43 MIN2017 OCT 25
Comments
Episode 20: Cancer Vaccine Renaissance

Episode 19: Revolutionary Thinking Required

In this episode we're exploring ways to jumpstart the immune system so that subsequent therapies can be more effective, especially in cold non-inflamed tumours. It is becoming increasingly clear that people with pre-existing immunity respond better to cancer immunotherapies. - What is it, why does it matter and how do we measure it? - What types of therapeutic approaches might be helpful for boosting it? In this show, you'll hear from some new and familiar expert voices alike: - Dr Jérôme Galon (INSERM) discusses the concept of pre-existing immunity and why it matters - Dr Carlos Paya (Immune Design) explains how a cancer testis vaccine can boost immunity in cold tumours such as sarcomas; - Dr Mario Sznol (Yale) talks about cytokines and why they may be an important factor to consider; - Drs Adi Diab (MD Anderson) and Jonathan Zalevsky (Nektar) discuss an immune agonist that may be useful in stimulating key immune cells and act synergistically with checkpoint blockade ; - Drs Frie...

34 MIN2017 SEP 1
Comments
Episode 19: Revolutionary Thinking Required

Episode 18: Shaping The Future

In the latest episode of Novel Targets, we take a look at new developments in breast cancer. Breast cancer can be organised into several distinct subsets for the purposes of treatment: - Hormone sensitive disease (HR+) - HER2+ - Triple negative breast cancer (TNBC) - Inflammatory breast cancer In addition, physicians also consider risk factors such as tumour size (T), whether the disease has spread to the lymph nodes (N) i.e. negative or positive, and whether there is metastasis (M), which has spread to other parts of the body. This means that lower risk breast cancers include those that are earlier stage, small in size, node negative, no metastasis present or are HR+. In contrast, high risk tumours include those that are larger, have node positive disease, or a HR-. Early stage disease (I-III) is usually reseactable and the aim of treatment is cure. Therapy given prior to surgery is known as neoadjuvant, while that administered after surgery is called adjuvant therapy. Stage IV dis...

47 MIN2017 JUL 4
Comments
Episode 18: Shaping The Future

Episode 17: Overcoming Immunotherapy Resistance

Welcome back to Season 3. In this episode we're tackling one of the hottest topics in cancer research, why do cancer immunotherapies work in some people, but not in others? Why do they stop working? If we want to obtain long durable responses, then we have to understand and overcome resistance. Most of the interviews you'll hear were recorded at the 2017 annual meeting of the American Association for Cancer Research (AACR) in Washington DC. In this episode you'll hear leading cancer immunotherapy experts including Dr Gordon Mills (MD Anderson Cancer Center), Dr Jason Luke (University of Chicago), Dr Daniel Chen (Genentech), Dr James Gulley (National Cancer Institute), Dr Leisha Emens (Johns Hopkins), Dr Ira Mellman (Genentech), Dr Julie Brahmer (Johns Hopkins), Dr Stephan Grupp (Children's Hospital of Philadelphia) and Dr Christine Brown (City of Hope). Some of the meaty topics covered include: - initial resistance - acquired resistance - immune escape - how we may be able to turn n...

35 MIN2017 MAY 6
Comments
Episode 17: Overcoming Immunotherapy Resistance

Latest Episodes

Episode 26: Coming Full Circle

The award of this year's Nobel prize in physiology or medicine to Dr Jim Allison and Dr Tasuku Honjo is a defining moment for cancer research that we want to recognize. You'll hear from Dr Allison on the very day he heard the announcement. We also take a closer look at what it takes to be a great scientist and explore the limitations on how many people the Nobel prize can recognize in a given year. If you want to increase your chance of winning, 1993 laureate Sir Richard Roberts FRS takes us through his "Ten Simple Rules to Win a Nobel Prize." We have come full circle in our journey over the last 3.5 years and now hear the results of a "practice changing" phase 3 cancer immunotherapy trial in triple negative breast cancer (TNBC) that we first talked about in the inaugural episode of the podcast, "The Checkpoints Show." There's also an update from the recent ESMO congress onresults from a phase 3 ovarian cancer trial that is potentially "life changing" for women with a BRCA mutation....

38 MIN2018 NOV 27
Comments
Episode 26: Coming Full Circle

Episode 25: In the shadow of T cells

In this episode we continue our journey looking at the innate immune system and focus on some important immune cells called natural killer (NK) cells and their potential in cancer immunotherapy. You'll hear from both academic and industry experts who are active in research in this field, including Dr Todd Fehniger (Washington University in St Louis), Dr Michael Caligiuri (City of Hope), Dr Jeff Miller (Minnesota), Prof Eric Vivier (Innate Pharma via Marseille Immunopole), Dr Nick Huntington (Walter & Eliza Hall Institute in Melbourne), Dr James Gulley (NCI), and Dr Deepak Sampath (Genentech). Some important topics we will cover: - What are NK cells? - What do the do? - How do they 'see'? - How can they be boosted? - What kind of approaches have been developed therapeutically? - What kind of clinical data have we seen so far? - What's the vision for the future of NK cell therapy development? You can find more detailed information about the topics discussed in the show notes on https:...

41 MIN2018 SEP 21
Comments
Episode 25: In the shadow of T cells

Episode 24: Immune System Choreography

In this episode we explore the innate immune system and find out what it is, what it does and why it matters in both health and disease. You'll hear various perspectives from both academic and industry experts who are active in research in this field, including Dr Glen Barber (Miami), Prof George Coukos (Lausanne), Dr Adi Diab (MD Anderson), Dr Tom Dubensky (Tempest Therapeutics via Aduro Biotech), Dr Tom Gajewski (Chicago), Dr Jonathan Lancaster (Myriad), Dr Ira Mellman (Genentech), Prof Eric Vivier (Innate Pharma via Marseille Immunopole/CIML), Dr Jonathan Zalevsky (Nektar Therapeutics). Some important topics we will cover: - What is the innate immune system? - What does it do? - How is it different from the adaptive immune system? - Is it really separate from the adaptive system? - STING (Stimulator of Interferon Genes) - Biomarkers - Toll-like Receptors (TLRs) You can find more detailed information about the topics discussed in the show notes on https://noveltargets.com. These i...

35 MIN2018 AUG 31
Comments
Episode 24: Immune System Choreography

Episode 23: Modulating the Signal

In this episode we take a look a look at how cytokines can be employed to modulate the tumour microenvironment in favourable ways. You'll hear various perspectives from numerous academic and industry experts who are active in research in this field, including Dr Mario Sznol (Yale), Dr James Gulley (NCI), Dr Adi Diab (MD Anderson), Dr Jonathan Zalevsky (Nektar Therapeutics), Dr Sanjeev Mariathasan (Genentech), Prof Tom Powles (Barts Cancer Institute), Dr Kunle Odunsi (Roswell Park), and Dr Renier Brentjens (Memorial Sloan Kettering). Some important topics that we will cover: - What are cytokines? - Why do they matter? - The good and bad effects they can induce on the tumour microenvironment (TME) - Interleukins - Transforming Growth Factor beta (TGFβ) - The increasingly important role for reverse translation research in helping to understand what's going on in the TME in order to improve rational future immuno-oncology (IO) combination approaches - Can we determine differences in re...

36 MIN2018 JUL 5
Comments
Episode 23: Modulating the Signal

Episode 22: Practice, Pitfalls, and Possibilities

Welcome back to Season 4! In this latest episode, we take a look at data from immunotherapy clinical trials from several different angles and investigate the challenges associated presented by different combination partners, control arms, patient populations, biomarkers, line of therapy, etc. When important phase 3 readouts hit the newswires, inevitable questions follow: - Is the data practice changing? - Which regimen should be used with which patient population? - What happens on the Weds after the conference in the clinic when a new patient presents; will oncologists do anything differently? While it's nice to have several positive trial results, how do physicians go about making sense of them? What are some of the hidden pitfalls of cross-trial comparisons that we should watch out for and consider? Professor Tom Powles (Barts Cancer Centre, London) is our narrator for this show and walks us through various challenges and opportunities that both investigators and oncologists face...

38 MIN2018 MAY 10
Comments
Episode 22: Practice, Pitfalls, and Possibilities

Episode 21: Playing With Fire

In this episode we're exploring some controversial issues in cancer research including real world versus clinical trial experience and immune related toxicities, as well as highlighting strength and weaknesses around some encouraging new data with several therapies in development for different hematologic malignancies. Not everything about cancer immunotherapies is positive -- there are challenges associated with this promising approach too. Despite what many people may believe, it's not just about merely tweaking one's immune system and the cancer goes away. Most of the interviews you'll hear were recorded at the 2017 annual meeting of the American Society of Hematology (ASH) in Atlanta. In this episode you'll hear leading experts, including Drs Paul Richardson and Philippe Armande (Dana-Farber), Dr John Leonard (Weill Cornell), Dr Ian Flinn (Sarah Cannon), Dr Nancy Simonian (Syros) and Drs Michael Wenger and Deepak Sampath (Genentech). Some of the topics covered include: * Real wo...

44 MIN2018 JAN 6
Comments
Episode 21: Playing With Fire

Episode 20: Cancer Vaccine Renaissance

In this latest episode we're exploring an up and coming area of cancer research, namely therapeutic cancer vaccines. If we want to jumpstart the immune system in cold/non-inflamed/desert tumours, then we need to find ways to attract more T cells into the tumour(s). Cancer vaccines can potentially do that but they have had a bit of a chequered history, with many failures and at least in the US, only one has been approved by the FDA to date. In this show you'll hear from leading cancer immunotherapy experts involved in cancer vaccine research, including Dr Cathy Wu (Dana Farber), Prof Ton Schumacher (Netherlands Cancer Institute), Prof Ugur Sahin (BioNTech and TRON), Prof Kees Melief (Leiden and ISA Pharma), Prof George Coukos (Lausanne), and Dr Ira Mellman (Genentech). Some important topics we cover include: - What's different about the next generation cancer vaccine approaches? - Neoantigen and neoepitope approaches - DNA and RNA vaccines - HPV vaccines - Dendritic cell vaccines - I...

43 MIN2017 OCT 25
Comments
Episode 20: Cancer Vaccine Renaissance

Episode 19: Revolutionary Thinking Required

In this episode we're exploring ways to jumpstart the immune system so that subsequent therapies can be more effective, especially in cold non-inflamed tumours. It is becoming increasingly clear that people with pre-existing immunity respond better to cancer immunotherapies. - What is it, why does it matter and how do we measure it? - What types of therapeutic approaches might be helpful for boosting it? In this show, you'll hear from some new and familiar expert voices alike: - Dr Jérôme Galon (INSERM) discusses the concept of pre-existing immunity and why it matters - Dr Carlos Paya (Immune Design) explains how a cancer testis vaccine can boost immunity in cold tumours such as sarcomas; - Dr Mario Sznol (Yale) talks about cytokines and why they may be an important factor to consider; - Drs Adi Diab (MD Anderson) and Jonathan Zalevsky (Nektar) discuss an immune agonist that may be useful in stimulating key immune cells and act synergistically with checkpoint blockade ; - Drs Frie...

34 MIN2017 SEP 1
Comments
Episode 19: Revolutionary Thinking Required

Episode 18: Shaping The Future

In the latest episode of Novel Targets, we take a look at new developments in breast cancer. Breast cancer can be organised into several distinct subsets for the purposes of treatment: - Hormone sensitive disease (HR+) - HER2+ - Triple negative breast cancer (TNBC) - Inflammatory breast cancer In addition, physicians also consider risk factors such as tumour size (T), whether the disease has spread to the lymph nodes (N) i.e. negative or positive, and whether there is metastasis (M), which has spread to other parts of the body. This means that lower risk breast cancers include those that are earlier stage, small in size, node negative, no metastasis present or are HR+. In contrast, high risk tumours include those that are larger, have node positive disease, or a HR-. Early stage disease (I-III) is usually reseactable and the aim of treatment is cure. Therapy given prior to surgery is known as neoadjuvant, while that administered after surgery is called adjuvant therapy. Stage IV dis...

47 MIN2017 JUL 4
Comments
Episode 18: Shaping The Future

Episode 17: Overcoming Immunotherapy Resistance

Welcome back to Season 3. In this episode we're tackling one of the hottest topics in cancer research, why do cancer immunotherapies work in some people, but not in others? Why do they stop working? If we want to obtain long durable responses, then we have to understand and overcome resistance. Most of the interviews you'll hear were recorded at the 2017 annual meeting of the American Association for Cancer Research (AACR) in Washington DC. In this episode you'll hear leading cancer immunotherapy experts including Dr Gordon Mills (MD Anderson Cancer Center), Dr Jason Luke (University of Chicago), Dr Daniel Chen (Genentech), Dr James Gulley (National Cancer Institute), Dr Leisha Emens (Johns Hopkins), Dr Ira Mellman (Genentech), Dr Julie Brahmer (Johns Hopkins), Dr Stephan Grupp (Children's Hospital of Philadelphia) and Dr Christine Brown (City of Hope). Some of the meaty topics covered include: - initial resistance - acquired resistance - immune escape - how we may be able to turn n...

35 MIN2017 MAY 6
Comments
Episode 17: Overcoming Immunotherapy Resistance
hmly
himalayaプレミアムへようこそ聴き放題のオーディオブックをお楽しみください。